Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 2798 • 2016 ACR/ARHP Annual Meeting
Multi-Center Validation of Platelet Bound C4d, a Biomarker for Systemic Lupus Erythematosus
Richard Furie¹, Anca D. Askanase², Kenneth Kalunian³, Elena Massarotti⁴, Rosalind Ramsey-Goldman⁵, Daniel J Wallace⁶, Stuart L. Silverman⁷, Smitha Reddy⁸, Puja Chitkara⁹, Chaim Putterman¹⁰, Christopher Collins¹¹, Jill P. Buyon¹², Cristina Arriens¹³, Tyler O'Malley¹⁴, Roberta Alexander¹⁵, Derren Barken¹⁶, John Conklin¹⁷, Susan Manzi¹⁸, Joseph Ahearn¹⁹, Arthur Weinstein²⁰ and Thierry Dervieux¹⁴, ¹North Shore University Hospital, Great Neck, NY, ²Medicine, Rheumatology, Columbia University Medical Center, New York, NY, ³Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ⁴Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, ⁵FSM, Northwestern University, Chicago, IL, ⁶Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Cedars, Beverly Hills, CA, ⁸Arthritis Care and Research Center, Inc., Poway, CA, ⁹Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA, ¹⁰Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ¹¹MedStar Washington Hospital Center, Washington, DC, ¹²Medicine, New York University School of Medicine, New York, NY, ¹³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Research and Development, Exagen Diagnostics, Vista, CA, ¹⁵Research & Development, Exagen Diagnostics, Vista, CA, ¹⁶Exagen Diagnostics, Vista, CA, ¹⁷1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ¹⁸Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁹Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, ²⁰Rheumatology Section, Washington Hospital Center, Washington, DC
Background/Purpose: Previous studies have established the value of measuring complement activation products (C4d) bound to platelets (PC4d) for the diagnosis and monitoring of Systemic Lupus…
Abstract Number: 920 • 2016 ACR/ARHP Annual Meeting
Autoantigen-Specific T Cell and Antibody Reactivity to a Human Gut Commensal in Antiphospholipid Syndrome
William Ruff¹, Carina Dehner², Alex Roth¹, Silvio M. Vieira¹, Cassyanne L. Aguiar^3,4, Andrew Goodman⁵, Doruk Erkan⁶ and Martin Kriegel¹, ¹Immunobiology, Yale School of Medicine, New Haven, CT, ²Immunobiology, Yale School of Medicine, new haven, CT, ³Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Cohen Children's Medical Center of New York/ Hofstra Northwell School of Medicine, Pediatric Rheumatology, New York, NY, ⁵Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Autoantigen-specific T Cell and Antibody Reactivity to a Human Gut Commensal in Antiphospholipid Syndrome William Ruff1, Carina Dehner1, Alex Roth1, Silvio M. Vieira1, Cassyanne L.…
Abstract Number: 2919 • 2016 ACR/ARHP Annual Meeting
Prevalence of Antiphospholipid Antibodies and Their Clinical Associations in Systemic Sclerosis: Data from a French Cohort
Angélique Lemaire^1,2, Vincent Sobanski^2,3,4,5, Jonathan Giovannelli⁶, Eric Hachulla^1,2,4,5, Sylvain Dubucquoi^4,7, Marc Lambert^1,2,4,5, Pierre-Yves Hatron^1,2,6 and David Launay^1,2,4,5, ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ²CHU Lille, Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), F-59000 Lille, France, Lille, France, ³CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, ⁴Univ. Lille, U995, Lille Inflammation Research International Center (LIRIC), F-59000 Lille, France, Lille, France, ⁵Inserm, U995, F-59000 Lille, France, Lille, France, ⁶Univ Lille, CHU Lille, F-59000 Lille, France, Lille, France, ⁷CHU Lille, Laboratoire d’Immunologie, F-59000 Lille, France, Lille, France
Background/Purpose: Antiphospholipid antibodies (aPL) have been found in patients with various autoimmune and rheumatic diseases, including systemic sclerosis (SSc). However, in the absence of clinical…
Abstract Number: 1062 • 2016 ACR/ARHP Annual Meeting
Non-Conventional Antiphospholipid Antibodies in Patients with Clinical Obstetrical APS: Prevalence and Pregnancies Treatment Efficacy
ARSENE MEKINIAN¹, Marie Charlotte Bourrienne², LIONEL CARBILLON³, AMELIE BENBARA⁴, SYLVIE CHOLLET MARTIN⁵, AHMED TIGAIZIN³, Francois Montestruc⁶, Olivier Fain⁷ and Pascale Nicaise-Roland⁸, ¹SAINT ANTOINE HOSPITAL, PARIS, France, ²Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, paris, France, ³JEAN VERDIER HOSPITAL, BONDY, France, ⁴JEAN VERDIER HOSPITAL, PARIS, France, ⁵UNITE HYPERSENSIBILITE, PARIS, France, ⁶exystat, PARis, France, ⁷Internal Medicine Department, Saint Antoine Hospital, Paris, France, ⁸Immunology Department, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France
Background/Purpose: To describe the prevalence of non-conventional APL in patients with obstetrical APS pregnancy adverse outcome without conventional APL and the impact of treatment on…
Abstract Number: 2961 • 2016 ACR/ARHP Annual Meeting
Antiphospoholipid Antibodies in Adult IgA Vasculitis: Aps/PT Antibodies As a Potential Marker of Renal Involvement?
Alojzija Hocevar, Jaka Ostrovrsnik, Polona Žigon, Saša Čučnik, Ziga Rotar and Matija Tomšič, Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Increased prevalence of IgA aCL and anti-PS/PT antibodies has been described in adult IgAV, making them potential markers of disease activity1. The aim of our…
Abstract Number: 1066 • 2016 ACR/ARHP Annual Meeting
History of Lupus Nephritis Is an Independent Risk Factor for Thrombosis in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies
Vinicius Domingues¹, Janet Nwaukoni², Jill P. Buyon³ and H. Michael Belmont⁴, ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Few studies have analyzed the risk factors for thrombosis in Systemic Lupus Erythematosus (SLE) patients with antiphospholipid antibodies (aPL) and most had small sample…
Abstract Number: 2001 • 2015 ACR/ARHP Annual Meeting
Reduction of HLA Class II Expression and Beta-2-Glycoprotein I Presentation By Fluvastatin in Vitro and in Vivo: Possible Mechanism of Statin-Induced-Deprocoagulation in the Antiphospholipid Syndrome
Toshiyuki Watanabe^1,2, Kenji Oku¹, Olga Amengual¹, Ryo Hisada¹, Kazumasa Ohmura¹, Haruki Shida¹, Yuka Shimizu¹, Masaru Kato¹, Toshiyuki Bohgaki¹, Tetsuya Horita¹, Shinsuke Yasuda¹, Akihiro Ishizu³, Hisashi Arase⁴ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²3rd Department of Internal medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan, ³Faculty of Health Sciences, Hokkaido University, Sapporo, Japan, ⁴Laboratory of Immunochemistry, WPI Immunology Frontier Research Center, Osaka University, Suita, Japan
Background/Purpose: Human leukocyte antigen (HLA)-DRB1*07:01 is one of the susceptibility alleles for antiphospholipid syndrome (APS). Recently we have reported that beta-2-glycoprotein I (b2GPI) /HLA class…
Abstract Number: 2180 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors
Maria Gerosa^1,2, Paola Adele Lonati³, Tania Ubiali¹, Martina Cornalba¹, Maria Orietta Borghi^1,4 and Pier Luigi Meroni^1,2,5, ¹Department of Clinical Sciences and Community Health, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ²Division of Rheumatology, Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy, ³Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Jamaica, ⁴Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁵Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients display high levels of the cell-bound complement activation factor C4d deposits on erythrocytes, B lymphocytes and platelets. In particular,…
Abstract Number: 2182 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Livedo Reticularis Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Ersilia M. DeFilippis¹, Denis Wahl² and Stephane Zuily², ¹Department of Medicine, Brigham and Women's Hospital, Boston, MA, ²CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France
Background/Purpose : Livedo reticularis (LR) is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our…
Abstract Number: 2185 • 2015 ACR/ARHP Annual Meeting
Small but Clinically Insignificant Decreases in Antiphospholipid Antibody Titers Occur in aPL-Positive Patients during Pregnancy
Cécile Yelnik^1,2, Flint Porter^3,4, Ware D. Branch^3,4, Jill P. Buyon⁵, Marta Guerra⁶, Carl Laskin⁷, Michael Lockshin⁸, Michelle Petri⁹, Joan T. Merrill¹⁰, Lisa R. Sammaritano¹¹, Mary D. Stephenson¹², Mimi Y. Kim¹³ and Jane E. Salmon^11,14, ¹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ²Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ³University of Utah, Salt Lake City, UT, ⁴Intermountain Healthcare, Salt Lake City, UT, ⁵NYU School of Medicine, New York, NY, ⁶Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁷Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁸Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, ⁹Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²University of Illinois College of Medicine, Chicago, IL, ¹³Albert Einstein College of Medicine, Bronx, NY, ¹⁴Hospital for Special Surgery, New York, NY
Background/Purpose: The presence of aPL has been associated with pregnancy complications, but the evolution of aPL titers during pregnancy in aPL-positive patients and the utility…
Abstract Number: 2186 • 2015 ACR/ARHP Annual Meeting
The Role of Hydroxychloroquine Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies
Savino Sciascia¹, Beverely J Hunt², Eva Talavera-Garcia³, Gloria Lliso³, Munther Khamashta³ and Mª Jose Cuadrado⁴, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Thrombosis & Haemostasis, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, London, United Kingdom, ³Louise Coote Lupus Unit, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom
Background/Purpose: With good management, around 70% of pregnant women with Antiphospholipid Syndrome (APS) will deliver a viable live infant.However, current management does not prevent all…
Abstract Number: 2187 • 2015 ACR/ARHP Annual Meeting
Anti-Phosholipid Antibodies and Female Infertility: A Systematic Revision of Literature
Cecilia B. Chighizola¹, Guilherme Ramires de Jesus² and W. David Branch³, ¹Department of Clinical Sciences and Community Health, University of Milan, Istituto Auxologico Italiano, Cusano Milanino, Italy, ²Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT
Background/Purpose: Infertility is a common condition, affecting 8-12% of couples in childbearing age. Even though the association of aPL with infertility is highly debated, infertile…
Abstract Number: 2192 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Thrombocytopenia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
YU PEI CHOCK¹, DENIS WAHL² and STEPHANE ZUILY³, ¹KENT MEMORIAL HOSPITAL, WARWICK, RI, ²CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ³CHU de Nancy, Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Vascular Medicine Division, NANCY, France
Background/Purpose : Thrombocytopenia is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our objective was…
Abstract Number: 2193 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Hemolytic Anemia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
OZAN UNLU¹, DENIS WAHL^2,3 and STEPHANE ZUILY^3,4, ¹Rheumatology Department, Barbara Volcker Center for Women and Rheumatic Disease, New York, NY, ²CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France, ³Inserm, UMR_S 1116, Nancy, France, ⁴CHU de Nancy, Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Vascular Medicine Division, NANCY, France
Title: Increased Risk of Hemolytic Anemia Associated With Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.Background/Purpose : Hemolytic anemia (HA)…
Abstract Number: 2194 • 2015 ACR/ARHP Annual Meeting
Anticoagulation and Longterm Outcomes in Patients with Renal Artery Stenosis and Antiphospholipid Syndrome
Alina Casian¹, Shirish Sangle (joint 1st author)², Sotiria Manoustathopoulou³ and David P. D'Cruz⁴, ¹Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, UK, London, United Kingdom, ²Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom, ³Department of Medicine, St. Thomas' Hospital, London, United Kingdom, ⁴Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom
Background/Purpose: Our previous data showed renal artery stenosis (RAS) is more prevalent in antiphospholipid syndrome(APS)(26%) compared to the general hypertensive population(8%),and anticoagulation with INR>=3 was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].